These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3404443)

  • 21. [Modulation by nitric oxide of vasopressin induced renal vasoconstriction varies with perfusate viscosity in the isolated rat kidney].
    Barthelmebs M; Loichot C; Nisato D; de Jong W; Grima M; Imbs JL
    Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1083-6. PubMed ID: 9749170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropeptide Y inhibits renin release by a pertussis toxin-sensitive mechanism.
    Hackenthal E; Aktories K; Jakobs KH; Lang RE
    Am J Physiol; 1987 Mar; 252(3 Pt 2):F543-50. PubMed ID: 3548437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of renal sympathetic nerves in regulating renovascular responses to angiotensin II in spontaneously hypertensive rats.
    Dubinion JH; Mi Z; Jackson EK
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1330-6. PubMed ID: 16537795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Norepinephrine-stimulated vascular prostacyclin synthesis. Receptor-dependent calcium channels control prostaglandin synthesis.
    Stewart D; Pountney E; Fitchett D
    Can J Physiol Pharmacol; 1984 Nov; 62(11):1341-7. PubMed ID: 6095981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of trifluoperazine on renin secretion of rat kidney slices.
    Churchill PC; Churchill MC
    J Pharmacol Exp Ther; 1983 Jan; 224(1):68-72. PubMed ID: 6336784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
    Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane.
    Fabi F; Argiolas L; Ruvolo G; del Basso P
    Br J Pharmacol; 1998 May; 124(1):101-10. PubMed ID: 9630349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of cyclosporine A-induced renal vasoconstriction in the rat.
    Rossi NF; Churchill PC; McDonald FD; Ellis VR
    J Pharmacol Exp Ther; 1989 Sep; 250(3):896-901. PubMed ID: 2778718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal by the calcium antagonist nisoldipine of norepinephrine-induced reduction of GFR: evidence for preferential antagonism of preglomerular vasoconstriction.
    Loutzenhiser R; Epstein M; Horton C; Sonke P
    J Pharmacol Exp Ther; 1985 Feb; 232(2):382-7. PubMed ID: 3968640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
    Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension.
    Wiest R; Jurzik L; Moleda L; Froh M; Schnabl B; von Hörsten S; Schölmerich J; Straub RH
    J Hepatol; 2006 Mar; 44(3):512-9. PubMed ID: 16324766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal microvascular actions of calcium antagonists.
    Loutzenhiser R; Epstein M
    J Am Soc Nephrol; 1990 Sep; 1(3 Suppl 1):S3-12. PubMed ID: 16989072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y.
    Bischoff A; Avramidis P; Erdbrügger W; Münter K; Michel MC
    Br J Pharmacol; 1997 Apr; 120(7):1335-43. PubMed ID: 9105710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of neuropeptide Y in renal sympathetic vasoconstriction: studies in normal and congestive heart failure rats.
    DiBona GF; Sawin LL
    J Lab Clin Med; 2001 Aug; 138(2):119-29. PubMed ID: 11477379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence that prostacyclin modulates the vascular actions of calcium in man.
    Nadler JL; McKay M; Campese V; Vrbanac J; Horton R
    J Clin Invest; 1986 Apr; 77(4):1278-84. PubMed ID: 3514678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostaglandins--modulation of adrenergic nervous system.
    Malik KU
    Fed Proc; 1978 Feb; 37(2):203-7. PubMed ID: 23968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo.
    Malmström RE; Lundberg JN; Weitzberg E
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):106-11. PubMed ID: 11819028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries.
    You J; Edvinsson L; Bryan RM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):77-84. PubMed ID: 11149671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action.
    Wahlestedt C; Edvinsson L; Ekblad E; Håkanson R
    J Pharmacol Exp Ther; 1985 Sep; 234(3):735-41. PubMed ID: 3928874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of calcium antagonists and calmodulin inhibitors on angiotensin II-induced prostaglandin productions in the isolated dog renal arteries.
    Satoh H; Suzuki J; Satoh S
    Biochem Biophys Res Commun; 1985 Jan; 126(1):464-70. PubMed ID: 3918533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.